Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

O'Connor DW. Epidemiology in Dementia, 3rd edn. 2005 Burns, O'Brien and Ames. Hodder Arnold, London.

Ritchie, 2004, A meta-analysis of randomised trials for the efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer's disease, Am J Geriatr Psychiatry, 12, 358, 10.1097/00019442-200407000-00003

Kang, 1987, The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor, Nature, 325, 733, 10.1038/325733a0

McLean, 1999, Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease, Ann Neurol, 46, 860, 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M

Walsh, 2007, Aβ oligomers—a decade of discovery, J Neurochem, 101, 1172, 10.1111/j.1471-4159.2006.04426.x

Lee, 2002, Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice, Proc Natl Acad Sci USA, 99, 7705, 10.1073/pnas.092034699

Schlief, 2005, NMDA-receptor activation mediates copper homeostasis in hippocampal neurons, J Neurosci, 25, 239, 10.1523/JNEUROSCI.3699-04.2005

Bush, 1994, Rapid induction of Alzheimer Aβ amyloid formation by zinc, Science, 265, 1464, 10.1126/science.8073293

Atwood, 1998, Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis, J Biol Chem, 273, 12817, 10.1074/jbc.273.21.12817

Opazo, 2002, Metalloenzyme-like activity of Alzheimer's disease β-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol and biological reducing agents to neurotoxic H2O2, J Biol Chem, 277, 40302, 10.1074/jbc.M206428200

Cherny, 2001, Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice, Neuron, 30, 665, 10.1016/S0896-6273(01)00317-8

Ritchie, 2003, Metal–protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer's disease: a pilot phase 2 clinical trial, Arch Neurol, 60, 1685, 10.1001/archneur.60.12.1685

Adlard, 2008, Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ, Neuron, 59, 43, 10.1016/j.neuron.2008.06.018

Cummings, 2007, Disease-modifying therapies for Alzheimer's disease: challenges to early intervention, Neurology, 69, 1622, 10.1212/01.wnl.0000295996.54210.69

Folstein, 1975, Mini mental state—a practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6

Rosen, 1984, A new rating scale for Alzheimer's disease, Am J Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356

Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol, 6, 734, 10.1016/S1474-4422(07)70178-3

Ritchie, 2004, Metal–protein attenuating compounds and Alzheimer's disease, Expert Opin Investig Drugs, 13, 1585, 10.1517/13543784.13.12.1585

Albers, 2008, Clioquinol, 857

Cummings, 1994, The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia, Neurology, 44, 2308, 10.1212/WNL.44.12.2308

Hansson, 2008, Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment, Neurobiol Aging

Blennow, 1995, Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease?, Mol Chem Neuropathol, 26, 231, 10.1007/BF02815140

Vanmechelen, 2000, Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization, Neurosci Lett, 285, 49, 10.1016/S0304-3940(00)01036-3

Harrison, 2007, A neuropsychological test battery for use in Alzheimer disease clinical trials, Arch Neurol, 64, 1323, 10.1001/archneur.64.9.1323

Aisen, 2006, A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease, Neurology, 67, 1757, 10.1212/01.wnl.0000244346.08950.64

Blennow, 2007, Longitudinal stability of CSF biomarkers in Alzheimer's disease, Neurosci Lett, 419, 18, 10.1016/j.neulet.2007.03.064

DeMattos, 2002, Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease, J Neurochem, 81, 229, 10.1046/j.1471-4159.2002.00889.x

Li, 1998, Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets, Lab Invest, 78, 461

Szlyk, 2002, Development and assessment of a Neuropsychological Battery to aid in predicting driving performance, J Rehabil Res Dev, 39, 483

Salloway, 2008, Disease-modifying therapies in Alzheimer's disease, Alzheimers Dement, 4, 65, 10.1016/j.jalz.2007.10.001